At the news
? BULLISHIMPACT 9/10 PREM14A filed Apr 17, 2026 at 16:45 ET
Centessa Pharmaceuticals (CNTA) is being acquired by Eli Lilly (LILY) in a $7.8B deal structured as a Scheme of Arrangement. Shareholders will receive $38.00 in cash per share plus a contingent value right (CVR) worth up to $9.00 per share based on future milestones. The deal, recommended by Centessa's board, is expected to close in Q3 2026 pending shareholder and regulatory approval.
- Eli Lilly is acquiring Centessa Pharmaceuticals for $38.00 per share in cash, plus a contingent value right (CVR) worth up to $9.00 per share.
- The total deal value is approximately $7.8 billion, including the CVR component.
- Centessa's board unanimously recommends shareholders vote in favor of the transaction.
- The deal structure is a Scheme of Arrangement under UK law, requiring approval from both shareholders and the UK High Court.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access